title: In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients.
abstract: To evaluate the clinical usefulness of IL-2 in myelodysplastic syndromes (MDS) the in vitro effects of interleukin-2 (IL-2) on blast cell proliferation, clonogenic activity, cytokine release and cell mediated cytotoxicity were examined in 49 MDS patients. Morphological analyses of bone marrow (BM) cytospin preparations showed a significant decrease in the number of blast cells in MDS after incubation with IL-2. Incubation of bone marrow mononuclear cells (BMMNCs) with IL-2 induced a significant increase in the number of CFU-GM in comparison with untreated controls. gamma-IFN and GM-CSF, but not alpha-TNF were found to be released in significant amounts by the BMMNCs cultured with IL-2. No significant differences in the surface phenotypes of fresh lymphocytes were observed between the normal and MDS subjects. After incubation with IL-2, we observed a significant increase in the number of CD3-/CD56+ cells in both normal and MDS subjects. Peripheral blood (PB) and BM NK activity against K562 was significantly greater in MDS after stimulation with IL-2. These data suggest the clinical usefulness of IL-2 in a large subgroup of patients as it may reduce the percentage of blasts and increase clonogenic capacity and cell-mediated cytotoxicity.
authors.affiliation: Servizio di Ematologia, Ospedale Maggiore, Milano, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Cortelezzi
authors.forename: B
authors.initials: B
authors.lastname: Sarina
authors.forename: C
authors.initials: C
authors.lastname: Cattaneo
authors.forename: M
authors.initials: M
authors.lastname: Pomati
authors.forename: I
authors.initials: I
authors.lastname: Silvestris
authors.forename: D
authors.initials: D
authors.lastname: Soligo
authors.forename: R
authors.initials: R
authors.lastname: Calori
authors.forename: M
authors.initials: M
authors.lastname: Di Stefano
authors.forename: C
authors.initials: C
authors.lastname: Hu
authors.forename: M
authors.initials: M
authors.lastname: Monza
authors.forename: L
authors.initials: L
authors.lastname: Radelli
authors.forename: A T
authors.initials: AT
authors.lastname: Maiolo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001853:Bone Marrow / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D019002:CD56 Antigen / Q000378:metabolism; D002455:Cell Division; D003114:Colony-Forming Units Assay; D016207:Cytokines / Q000378:metabolism*; D003602:Cytotoxicity, Immunologic; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism; D006098:Granulocytes / Q000473:pathology; D006801:Humans; D016130:Immunophenotyping; D007371:Interferon-gamma / Q000378:metabolism; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000276:immunology* / Q000473:pathology; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008264:Macrophages / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000276:immunology* / Q000378:metabolism / Q000473:pathology
chemical_list: D019002:CD56 Antigen; D016207:Cytokines; D007376:Interleukin-2; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor